[C5: eculizumab].
Copyright policy )[C5: eculizumab].
Eculizumab is a recombinant humanized monoclonal antibody that specifically binds to a C5 terminal complement and inhibits the cleavage of C5 to C5a and C5b through complement activation. Eculizumab has been used clinically for paroxysmal nocturnal hemoglobinuria. Clinical studies have been initiated for neurological disorders, such as, optic neuromyelitis and myasthenia gravis, mediated by the complement system. In addition, eculizumab is expected to be useful for the treatment of intractable neurological diseases.
- Kindai University Japan
Myasthenia Gravis, Neuromyelitis Optica, Hemoglobinuria, Paroxysmal, Animals, Complement C5, Humans, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized
Myasthenia Gravis, Neuromyelitis Optica, Hemoglobinuria, Paroxysmal, Animals, Complement C5, Humans, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!